Paradigm Shift in Metastatic TNBC to Trop2-Targeted Antibody-Drug Conjugates

By News Health
5 hours Ago

(MedPage Today) — BERLIN — Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic triple-negative breast cancer (TNBC) ineligible for immunotherapy, according to two randomized trials…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118038

Author :

Publish date : 2025-10-20 17:55:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Physician Exits From Medicare Increased in Vulnerable Areas

Cancer Study Links COVID Shots to Longer Survival

Adverse Event Risks Vary Among Asthma Biologics, FDA Data Show

Global Study Reports Rise in Several Cancers Among Adults of All Ages

Chemotherapy-Free Combo Improves Survival in Metastatic Colorectal Cancer

Primary Care Docs Spend This Many Hours Per Week Caring for Patients